Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
出版年份 2023 全文链接
标题
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
作者
关键词
-
出版物
Pharmaceuticals
Volume 16, Issue 4, Pages 614
出版商
MDPI AG
发表日期
2023-04-20
DOI
10.3390/ph16040614
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
- (2023) Justin Shaya et al. npj Genomic Medicine
- Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
- (2023) Jacob J. Adashek et al. npj Precision Oncology
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
- (2022) V. Subbiah et al. ANNALS OF ONCOLOGY
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
- (2022) George D. Demetri et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
- (2022) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting HER2-Mutant NSCLC — The Light Is On
- (2022) Antonio Passaro et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
- (2022) Ana Oaknin et al. Journal for ImmunoTherapy of Cancer
- Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
- (2022) Victor Moreno et al. Clinical Lung Cancer
- Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
- (2022) Jacob J. Adashek et al. MOLECULAR CANCER THERAPEUTICS
- Cancer: Slaying the 9-headed Hydra
- (2022) J.J. Adashek et al. ANNALS OF ONCOLOGY
- Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
- (2022) M. Maio et al. ANNALS OF ONCOLOGY
- Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
- (2022) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results.
- (2022) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study.
- (2022) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
- (2022) Alison M. Schram et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown
- (2022) Shumei Kato et al. Molecular Oncology
- Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
- (2022) Vivek Subbiah et al. NATURE MEDICINE
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
- (2022) Vivek Subbiah et al. LANCET ONCOLOGY
- Clinical trial design in the era of precision medicine
- (2022) Elena Fountzilas et al. Genome Medicine
- Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
- (2021) Shumei Kato et al. CLINICAL CANCER RESEARCH
- Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
- (2021) Harshabad Singh et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
- (2021) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
- (2021) Shumei Kato et al. JCI Insight
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- (2021) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.
- (2021) Dominique Berton et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary results of molecular screening for FGFR alterations (alts) in the RAGNAR histology-agnostic study with the FGFR-inhibitor (FGFRi) erdafitinib.
- (2021) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- (2021) Justin F Gainor et al. LANCET ONCOLOGY
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
- (2021) Milind Javle et al. LANCET ONCOLOGY
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- (2021) Vivek Subbiah et al. Lancet Diabetes & Endocrinology
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- (2021) Chiara Corti et al. Cancers
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
- (2021) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mismatch repair deficiency: The what, how and why it is important
- (2021) Maria C. Olave et al. GENES CHROMOSOMES & CANCER
- Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
- (2021) Patrick Y Wen et al. LANCET ONCOLOGY
- Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
- (2021) Jason K. Sicklick et al. Genome Medicine
- Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer
- (2021) Daniel Rosas et al. Cancers
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
- (2020) April K. S. Salama et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
- (2020) Jacob J. Adashek et al. Frontiers in Oncology
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- Selpercatinib Aimed at RET-Altered Cancers
- (2020) Razelle Kurzrock NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
- (2020) Lori J. Wirth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
- (2020) Andrea Sartore-Bianchi et al. ESMO Open
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
- (2020) Denis L. Jardim et al. CANCER CELL
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1–ALK fusion: a case report
- (2019) Kazunori Honda et al. INVESTIGATIONAL NEW DRUGS
- Detection of NRG1 Gene Fusions in Solid Tumors
- (2019) Sushma Jonna et al. CLINICAL CANCER RESEARCH
- PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?
- (2019) Jacob J Adashek et al. Future Oncology
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
- (2019) Jordi Rodon et al. NATURE MEDICINE
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
- (2019) Aaron M. Goodman et al. Cancer Immunology Research
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- RET fusions in solid tumors
- (2019) Andrew Y. Li et al. CANCER TREATMENT REVIEWS
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomics and the History of Precision Oncology
- (2019) Deborah B. Doroshow et al. Surgical Oncology Clinics of North America
- Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
- (2018) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
- (2018) Sumanta K. Pal et al. EUROPEAN UROLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Inflammatory Myofibroblastic Tumor Driven by Novel NUMA1-ALK Fusion Responds to ALK Inhibition
- (2018) Nisha Rao et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
- (2018) Patrick Schöffski et al. Lancet Respiratory Medicine
- Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- (2018) Michael M. Boyiadzis et al. Journal for ImmunoTherapy of Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- 756PInterim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
- (2018) A Hollebecque et al. ANNALS OF ONCOLOGY
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene
- (2017) Masafumi Saiki et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
- (2017) Aatur D. Singhi et al. Journal of the National Comprehensive Cancer Network
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALKFusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy
- (2017) Jeffrey S. Ross et al. ONCOLOGIST
- Targeting TRK family proteins in cancer
- (2017) Yekaterina B. Khotskaya et al. PHARMACOLOGY & THERAPEUTICS
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- The role of the ALK receptor in cancer biology
- (2016) B. Hallberg et al. ANNALS OF ONCOLOGY
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
- (2016) Apurva Jain et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms
- (2016) Maria Schwaederle et al. JAMA Oncology
- The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer
- (2015) Hong Jae Chon et al. ANNALS OF SURGICAL ONCOLOGY
- A note from history: Landmarks in history of cancer, part 7
- (2015) Steven I. Hajdu et al. CANCER
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
- (2015) Daniela Sia et al. Nature Communications
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test
- (2014) Rodrigo Dienstmann et al. Molecular Oncology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amino Acids and Immune Response: A Role for Cysteine, Glutamine, Phenylalanine, Tryptophan and Arginine in T-cell Function and Cancer?
- (2014) Angelos K. Sikalidis PATHOLOGY & ONCOLOGY RESEARCH
- Fool’s gold, lost treasures, and the randomized clinical trial
- (2013) David J Stewart et al. BMC CANCER
- A note from history: Landmarks in history of cancer, Part 6
- (2013) Steven I. Hajdu et al. CANCER
- Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma
- (2013) Yasuhito Arai et al. HEPATOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
- (2013) Brittany C Parker et al. JOURNAL OF PATHOLOGY
- Implementing personalized cancer genomics in clinical trials
- (2013) Richard Simon et al. NATURE REVIEWS DRUG DISCOVERY
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
- (2012) Jan J. Molenaar et al. NATURE
- ALKoma: A Cancer Subtype with a Shared Target
- (2012) Hiroyuki Mano Cancer Discovery
- A note from history: Landmarks in history of cancer, part 3
- (2011) Steven I. Hajdu CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started